Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Rating of "Buy" from Analysts

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) have been given a consensus rating of "Buy" by the five ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $65.25.

CORT has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday, October 31st. StockNews.com raised shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 31st. Truist Financial increased their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a "buy" rating in a research report on Monday, September 30th. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, September 18th. Finally, Sandler O'Neill reiterated a "buy" rating on shares of Corcept Therapeutics in a research report on Friday, October 18th.

Insider Activity at Corcept Therapeutics

In other news, insider Gary Charles Robb sold 3,101 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $35.71, for a total value of $110,736.71. Following the transaction, the insider now owns 23,190 shares of the company's stock, valued at $828,114.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider William Guyer sold 10,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total transaction of $353,000.00. Following the completion of the transaction, the insider now owns 6,039 shares of the company's stock, valued at approximately $213,176.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Charles Robb sold 3,101 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $35.71, for a total transaction of $110,736.71. Following the transaction, the insider now owns 23,190 shares of the company's stock, valued at approximately $828,114.90. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,101 shares of company stock worth $1,462,517 over the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Capital Performance Advisors LLP purchased a new position in Corcept Therapeutics in the 3rd quarter worth approximately $25,000. Park Place Capital Corp bought a new stake in shares of Corcept Therapeutics during the second quarter valued at approximately $32,000. Atwood & Palmer Inc. purchased a new position in shares of Corcept Therapeutics in the 2nd quarter valued at $35,000. Kathleen S. Wright Associates Inc. acquired a new position in shares of Corcept Therapeutics during the third quarter valued at about $36,000. Finally, Blue Trust Inc. boosted its holdings in shares of Corcept Therapeutics by 125.4% in the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company's stock valued at $115,000 after acquiring an additional 1,962 shares during the last quarter. Institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Trading Down 2.2 %

Corcept Therapeutics stock traded down $1.27 during trading on Tuesday, reaching $57.79. The company had a trading volume of 1,159,312 shares, compared to its average volume of 1,191,102. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of 46.87 and a beta of 0.45. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $61.66. The stock's 50 day moving average price is $44.79 and its two-hundred day moving average price is $36.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same quarter last year, the business posted $0.28 EPS. The company's revenue was up 47.7% on a year-over-year basis. As a group, equities analysts expect that Corcept Therapeutics will post 1.31 earnings per share for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.